U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473167) titled 'Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients' on Dec. 23, 2025.
Brief Summary: This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
Study Start Date: Aug. 03, 2023
Study Type: INTERVENTIONAL
Condition:
Relapsed Large B-cell Lymphoma
Refractory Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
High-grade B-cell Lymphoma (HGBL)
Transformed Follicular Lymphoma (TFL)
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Interven...